Ratings ICON Public Limited Company

Equities

ICLR

IE0005711209

Market Closed - Nasdaq Other stock markets 04:00:00 2023-12-04 pm EST			5-day change	1st Jan Change
266.61 ^USD	-1.02%		-1.04%	+37.25%

Dec. 04	Let's party like it's 2021
Dec. 04	ANALYST RECOMMENDATIONS : Adobe, Broadcom, Comcast, Fair Isaac, Salesforce...

Strengths

The company's profit outlook over the next few years is a strong asset.
Analysts covering this company mostly recommend stock overweighting or purchase.
Analyst opinion has improved significantly over the past four months.
Over the past twelve months, analysts' opinions have been strongly revised upwards.
The divergence of price targets given by the various analysts who make up the consensus is relatively low, suggesting a consensus method of evaluating the company and its prospects.

Weaknesses

The company's valuation in terms of earnings multiples is rather high. Indeed, the firm is getting paid 39.8 times its estimated earnings per share for the ongoing year.
The group usually releases earnings worse than estimated.

Ratings chart - Surperformance

Chart ESG Refinitiv

Sector : Biotechnology & Medical Research

	1st Jan change	Capi.	ESG Refinitiv
ICON PUBLIC LIMITED COMPANY	+37.25%	22 175 M $	B-
SEAGEN INC.	+65.85%	40 132 M $	B
IQVIA HOLDINGS INC.	+5.55%	39 586 M $	B
MODERNA, INC.	-55.53%	30 438 M $	B-
LONZA GROUP AG	-27.15%	28 571 M $	A
ALNYLAM PHARMACEUTICALS, INC.	-27.26%	21 511 M $	B
CELLTRION, INC.	+1.31%	17 412 M $	C
UNITED THERAPEUTICS CORPORATION	-13.72%	11 313 M $	B+
CHARLES RIVER LABORATORIES INTERNATIONAL, INC.	-7.93%	10 346 M $	C+
BIO-TECHNE CORPORATION	-21.21%	10 212 M $	B+

Investor Rating

Trading Rating

ESG Refinitiv

Financials

Sales growth

Earnings Growth

EBITDA / Sales

Profitability

Finances

Valuation

P/E ratio

EV / Sales

Price to Book

Price to Free Cash Flow

Yield

Momentum

1 year Revenue revision

4 months Revenue revision

7 days Revenue revision

1 year EPS revision

4 months EPS revision

Consensus

Analyst Opinion

Potential Price Target

4m Target Price Revision

4m Revision of opinion

12m Revision of opinion

Business Predictability

Analyst Coverage

Divergence of Estimates

Divergence of analysts' opinions

Divergence of Target Price

Earnings quality

Environment

Emissions

Innovation

Use of resources

Governance

CSR Strategy

Management

Shareholders

Controversy

Technical analysis

ST Timing

MT Timing

LT Timing

RSI

Bollinger Spread

Unusual volumes